EMERYVILLE, Calif., Feb. 6, 2025 — (Nasdaq: DVAX), Dynavax, a commercial-stage biopharmaceutical company specializing in innovative vaccines, will release its financial results for the fourth quarter and full year of 2024 on Thursday, February 20, 2025, after the U.S. financial markets close.

Dynavax will conduct a conference call and live webcast on Thursday, February 20, 2025, at 4:30 p.m. ET/1:30 p.m. PT.

Access the live audio webcast on the “Events & Presentations” page within the “Investors” section of the Company’s website at  A replay of the webcast will be accessible for 30 days post-event.

To join the call, participants must register using the . Participants should connect approximately 10 minutes beforehand.

About Dynavax
Dynavax, a commercial-stage biopharmaceutical company, develops and markets cutting-edge vaccines to combat infectious diseases globally. The Company markets HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], approved in the U.S., European Union, and Great Britain for preventing hepatitis B in adults 18 and older, and CpG 1018^® adjuvant, used in HEPLISAV-B and several adjuvanted COVID-19 vaccines. For details on our products and pipeline, visit .

For Investors/Media:
Paul Cox

510-665-0499 

Nicole Arndt

510-665-7264

SOURCE Dynavax Technologies